The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-based Discussion Webinar (2020)

October 21, 2020

Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).

SUO strongly encourages that fellows participate in at least one SUO-sponsored educational course as available during their fellowship in addition to attending the Annual/Winter Meeting and the AUA/Spring Meeting. This educational course satisfies this recommendation.

Join Course Directors, Michael S. Cookson, MD, MMHC and David F. Jarrard, MD, virtually on Wednesday, October 21 for an educational initiative in advanced prostate cancer.


As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). Topics will include the latest on Genetic Testing in Advanced Prostate Cancer and the Role of Immunotherapy and PARP Inhibitors.

Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive live virtual forum will focus on the application of knowledge with case studies and small group discussion via breakout rooms integrated throughout the day. A flipped classroom approach will be utilized. Register early to receive the Prework Library, which is now available. Participants will be expected to complete the Prework Library in advance of virtually attending the live course - complete the pre-work on your own time, at your convenience. Then, come prepared on October 21 to actively engage with peers as you apply what you've learned.

Pre-registration is required and space is limited.

Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer. This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer.


The Live Forum will cover the following topics:

  • Identification of High Risk Disease and Initial Management of Biochemical Recurrence
  • Imaging of Advanced Prostate Cancer
  • Management of mHSPC: A Case-based Discussion of Chemohormonal Therapy and the Evolving Role of Local Therapy in Oligometastatic Disease
  • M0 CRPC: Treatment Options and Goals of Therapy
  • Genetic Testing in Advanced Prostate Cancer
  • Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents in mHSPC and CRPC
  • Role of Immunotherapy and PARP Inhibitors
  • Radionuclide Therapy and Bone Health
  • Role of Chemotherapy and Treatment Sequencing

*Visit the program tab for full details.

Acknowledgements

This educational activity is supported by independent educational grants from:

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck

Course Registration Fees
 

AUA/SUO's The Changing Landscape of Advanced Prostate Cancer Treatment: A Case-based Discussion Webinar (2020) Registration Fees

Membership CategoryLive Course 
AUA Member$25
AUA Non-Member $25

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
  • Nurse

Learning Objectives

At the conclusion of this activity, participants will be able to:  

PRACTICE GAP #1 (DISEASE STATE)

  1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
  2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
  4. Describe the treatment options and outcomes for newly diagnosed mHSPC.
  5. Explain the implications of CRPC on the management of both M0 and M1.
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC.

PRACTICE GAP #2 (GUIDELINES)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  5. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

PRACTICE GAP #3 (ANDROGEN AXIS)

  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
  4. Discuss new uses for androgen axis agents in M0 CRPC.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND CO-MORBIDITY)

  1. Identify approved chemotherapeutics, immunotherapy and PARP Inhibitors for mCRPC.
  2. Describe indications and contraindications for chemotherapy, immunotherapy and PARP Inhibitors in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Identify germ-line and somatic mutations and implications for treatment in mCRPC.
  5. Discuss treatment sequencing.

PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.

PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)

  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
Course summary
Available credit: 
  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Non-Physician Participation
Course opens: 
08/24/2020
Course expires: 
10/21/2023
Event starts: 
10/21/2020 - 9:00am
Event ends: 
10/21/2020 - 4:45pm
Price:
$25.00
Rating: 
0

The Changing Landscape of Advanced Prostate Cancer Treatment:
A Guidelines and Case-based Discussion Webinar

Wednesday, October 21, 2020 (All times are listed in EDT- Eastern Daylight Time.)

Agenda
9:00 – 9:05 a.m.Welcome
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
9:05 – 9:15 a.m.Pre-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
Session 1
9:15 – 9:35 a.m.Identification of High Risk Disease and Initial Management of Biochemical Recurrence
Dr. Boorjian
9:35 – 9:50 a.m.Imaging of Advanced Prostate Cancer
Dr. Stratton
9:50 – 10:10 a.m.Management of mHSPC: A Case-based Discussion of Chemohormonal Therapy and the Evolving Role of Local Therapy in Oligometastatic Disease
Moderators: David F. Jarrard, MD & Dr. Lang
10:10 – 10:30 a.m.M0 CRPC: Treatment Options and Goals of Therapy
Dr. Cookson
10:30 a.m. – 10:45Break
10:45 – 11:10 a.m.Genetic Testing in Advanced Prostate Cancer
Dr. Gomella
11:10 – 11:35 a.m.Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents in mHSPC and CRPC
Dr. Jarrard
11:35 – 12:35 p.m.Case-based Roundtable Discussions
  • Case #1 –BCR and mHSPC – Dr. Boorjian
  • Case #2 - M0 CRPC - Dr. Cookson

Roundtable Discussants: All Faculty
12:35 – 1:35 p.m.

A Non-CME Lunchtime Symposium supported by Astellas Pharma US and Pfizer Oncology

Elevate Care in Advanced Prostate Cancer

Neal D. Shore, MD, FACS

Session 2
1:35 – 1:55 p.m.Role of Immunotherapy and PARP Inhibitors
Dr. Morgans
1:55 – 2:15 p.m.Radionuclide Therapy and Bone Health
Dr. Boorjian
2:15 – 3:05 p.m.Case-based Roundtable Discussion: Chemotherapy-naive
  • Case #3: Early M1 CRPC Management (Docetaxel vs. Oral Agents vs. Immunotherapy) – Dr. Stratton
  • Case #4: Advanced M1 CRPC (Docetaxel and Ra-223) – Dr. Morgans

Roundtable Discussants: All Faculty
3:05 – 3:20 p.m.Break
Session 3
3:20 – 3:45 p.m.Role of Chemotherapy and Treatment Sequencing
Dr. Lang
3:45 – 4:45 p.m.Case-based Roundtable Discussion: Post-Chemotherapy
  • Case #5: Role of Genetic Testing in Advanced M1 CRPC (Immunotherapy or PARP Inhibitors) – Dr. Gomella
  • Case #6: M1 CRPC Post-docetaxel Chemotherapy and End-of-Life Care (Neuroendocrine) – Dr. Lang

Roundtable Discussants: All Faculty

The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-based Discussion Webinar (2020) will be held virtually on Wednesday, October 21, 2020 at 9:00 AM EST.

***Instructions***

  1. Click the "Register" tab.
  2. Complete payment. If prompted, click “update your profile”.
  3. Follow the instructions to complete the registration process.

Disclosures 

Faculty and Course Director disclosures will be posted here before the start of the course date.

 

Education Council Disclosures

PDF iconEducation Council Disclosures

 

AUA Office of Education Staff has nothing to disclose.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Non-Physician Participation

Price

Price:
$25.00
Please login or register to take this course.

After registration, follow these instructions to join the webinar:
 

  1. Click the "Add to cart" button.
  2. Follow the instructions to complete the payment process.
  3. Click “Start” under Live Webinar: The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-based Discussion Webinar (2020) in the Course Progress pane. 
  4. Click on "Join the meeting" to initiate an email confirmation from ZOOM to add to your calendar.

Course Registration Fees

Membership CategoryLive Course 
AUA Member$25
AUA Non-Member $25

 


Cancellation Policy
 

An administrative fee of 15% is assessed if registration is cancelled up to six weeks prior to the course. If registration is cancelled four to six weeks from the course, the cancellation fee is 50% of the registration fee paid. No registration fees will be refunded less than four weeks prior to the course.

Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before September 9, 2020. If AUA Education & Research cancels this course, registration fees will be refunded in full and notification will be sent by September 16, 2020.

 

Attendee Information & Policies
 

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance, please contact education@auanet.org.